CHRS Coherus BioSciences
- 2.120
- -0.050-2.30%
- 2.190
- +0.070+3.30%
Coherus BioSciences News
Coherus Biosciences (CHRS) Gets a Hold From Maxim Group
Analysts Conflicted on These Healthcare Names: Spero Therapeutics (SPRO) and Coherus Biosciences (CHRS)
Coherus BioSciences Is Maintained at Buy by Truist Securities
Coherus BioSciences Is Maintained at Buy by Truist Securities
Express News | Truist Securities Maintains Buy on Coherus BioSciences, Lowers Price Target to $7
Express News | Coherus BioSciences Inc : Truist Securities Cuts Target Price to $7 From $8
Coherus BioSciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
There's been a notable change in appetite for Coherus BioSciences, Inc. (NASDAQ:CHRS) shares in the week since its quarterly report, with the stock down 16% to US$1.90. It looks to have been a d
Coherus BioSciences Is Maintained at Buy by HC Wainwright & Co.
Coherus BioSciences Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Raises Price Target to $12
Coherus BioSciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 559.34% HC Wainwright & Co. $11 → $12 Maintains Buy 03/20/2024 504.4% HC Wainwright & Co. $13 →
Express News | Coherus BioSciences Shares Are Trading Lower After the Company Reported Better-than-expected Q1 Financial Results
Earnings Call Summary | Coherus BioSciences(CHRS.US) Q1 2024 Earnings Conference
The following is a summary of the Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript:Financial Performance:Coherus BioSciences reported a net product revenue of $76.7 million in Q1 2024
Express News | Coherus BioSciences Inc : H.c. Wainwright Raises Target Price to $12
Buy Rating Affirmed for Coherus Biosciences Amid Strong Udenyca Sales and Strategic Financial Management
Coherus BioSciences | 10-Q: Quarterly report
Express News | Coherus BioSciences Inc: Sees Combined R&D and SG&a Expenses for 2024 to Be in Range of $250 to $265 Mln
Express News | Coherus BioSciences Inc: New Debt and Royalty Financing Replaces $75 Mln Term Loan, With Debt Maturity of May 2029
Earnings Flash (CHRS) COHERUS BIOSCIENCES Posts Q1 Revenue $77.1M, Vs. Street Est of $83.8M
04:04 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (CHRS) COHERUS BIOSCIENCES Posts Q1 Revenue $77.1M, vs. Street Est of $83.8M
Express News | Coherus BioSciences Q1 Net Income USD 102.875 Million
Express News | Coherus BioSciences Q1 EPS USD 0.83
Express News | Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
Analysis
Price Target
No Data
